IntelliSyn is a drug discovery group with proven experience from major pharma and has a demonstrated track record of delivering clinical candidates. Our clients include academics, foundations, biotechs, venture groups, and major pharma.
We provide major pharma experience and capabilities in synthesis, medicinal chemistry, and drug development. We work with innovator groups by providing highly efficient and cost effective med chem design, synthesis, and optimization to progress projects from hit to final validated clinical candidates (ready for IND-enabling tox). We specialize in accelerating projects at the interface between early target identification and large pharma investment.
Our core focus includes CNS therapeutics, oncology, and epigenetics. We have specialized screening capabilities for GPCR and ion channel targets with on-site technologies, including Flipr, Hammamatsu, and PatchXpress.
We work on various terms according to the innovator’s needs, from simple fee-for-service to full co-investment. Irrespective of the type of collaboration, we commit to providing quality, integrity, value, and innovation to every project we serve.